Photo by  olga-kononen on Unsplash
Photo by olga-kononen on Unsplash

New treatment for superbugs shows promise

Embargoed until: Publicly released:
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.

Case study: A study involving observations of a single patient or group of patients.

People: This is a study based on research using people.

Bacteriophages, a type of virus that infects and kills bacteria, could be used to treat antibiotic resistant ‘superbugs’ which are evolving rapidly around the world. In 2016, a 30 year old woman suffered gruesome injuries from a suicide bombing in Brussels Airport. The victim experienced extensive complications for over three years after her wound became infected with antibiotic resistant bacteria. After 700 days of ineffective antibiotic treatment, the patient began bacteriophage therapy alongside other interventions, and three months later her condition drastically improved, and her infection could no longer be detected. The bacteriophages used in this type of therapy need to be precisely adapted to work against specific mutations in each bacterial infection, which is a lengthy and complicated process.

Journal/conference: Nature Communications

Link to research (DOI): 10.1038/s41467-021-27656-z

Organisation/s: CUB-Erasme Hospital, Clinic of Infectious Diseases, Brussels, Belgium

Funder: N/A

Media release

From: Springer Nature

Microbiology: Bacteriophage therapy helps treat pan-drug resistant bacterial infection

Combining bacteriophage therapy with antibiotics markedly improved the condition of a 30-year-old patient with a fracture-related, pan-drug-resistant Klebsiella pneumoniae infection, according to a study in Nature Communications. This case study demonstrates the promise of bacteriophage treatments for drug-resistant bacterial infections.

Pan-drug-resistant bacteria — or ‘superbugs’ — are resistant to all commercially available antimicrobial agents and are an increasing public health threat as treatment options are limited. An alternative approach is to use bacteriophages, a type of virus that infects and kills bacteria.

Anaïs Eskenazi and colleagues report the results of a six-day course of bacteriophage therapy for a 30-year-old female victim of a bombing with a fracture-related, pan-drug-resistant Klebsiella pneumoniae infection for whom antibiotic treatment had failed for nearly two years. The authors selected and adapted a bacteriophage for optimal killing of the bacteria, specific to the strain of Klebsiella pneumoniae that had been recovered from the patient. A combination of this pre-adapted bacteriophage — applied locally to the wound — and antibiotics were used. Three months later the patient’s general condition had improved, the wound was healing and no evidence of bacterial infection was found. Three years after the phage-antibiotic combination treatment, the patient had regained mobility and was able to participate in sporting events.

Although this case study demonstrates the potential of bacteriophage therapy, complex personalization of treatment is likely necessary, making application for larger patient groups challenging, the authors conclude.

Attachments:

Note: Not all attachments are visible to the general public

News for:

International

Media contact details for this story are only visible to registered journalists.